Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Duality Biotherapeutics, Inc.
映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 9606)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 30, 2025

References are made to the notice of extraordinary general meeting (the "**Notice**") and the circular (the "**Circular**") of Duality Biotherapeutics, Inc. (the "**Company**") both dated December 14, 2025. Unless otherwise indicated, capitalized terms used herein have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of the ordinary resolutions proposed at the EGM were as follows.

ORDINARY RESOLUTIONS		**Number of votes cast and approximate percentage of total number of votes cast**	
		For	**Against**
1.	subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") granting the approval for the listing of, and permission to deal in, the Shares which may fall to be allotted and issued pursuant to the vesting of the awards (the "**Awards**") that may be granted under the 2025 Share Scheme (the rules of which are contained in the document marked "A" produced to the EGM and initialed by the chairman of the EGM for the purpose of identification) (the "**2025 Share Scheme**"), the 2025 Share Scheme be and is hereby approved and adopted and the Directors and its Delegate be and are hereby authorized to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2025 Share Scheme including without limitation: (i) to administer the 2025 Share Scheme;	47,758,018 (96.337189%)	1,815,795 (3.662811%)

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
	(ii) to modify and/or amend the 2025 Share Scheme from time to time provided that such modification and/or amendment is effected in accordance with the provisions of the 2025 Share Scheme relating to modification and/or amendment and subject to Chapter 17 of the Listing Rules; (iii) to allot and issue from time to time such number of Shares as may be required to be allotted and issued and to procure the transfer of and deal with the Shares (including treasury shares, as the case may be) pursuant to the vesting of the Awards granted under the 2025 Share Scheme; (iv) to make application at the appropriate time or times to the Stock Exchange for the listing of, and permission to deal in any Shares which may thereafter from time to time be allotted and issued pursuant to the vesting of the Awards granted under the 2025 Share Scheme; and (v) to consent, if they deem fit and expedient, to such conditions, modifications and/or variations as may be required or imposed by the relevant authorities in relation to the 2025 Share Scheme.		
2.	the scheme mandate limit of the 2025 Share Scheme be and is hereby approved and adopted.	47,759,345 (96.339866%)	1,814,468 (3.660134%)
3.	the Service Provider Sublimit under the 2025 Share Scheme be and is hereby approved and adopted.	46,713,835 (94.230869%)	2,859,978 (5.769131%)

As more than 50% of the votes held by Shareholders present at the EGM in person or by proxy were cast in favour of the resolutions no. 1 to no. 3, the resolutions no. 1 to no. 3 proposed at the EGM were duly passed as ordinary resolutions of the Company.

As at the date of the EGM, the total number of issued Shares of the Company was 89,392,714 Shares which represented the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the EGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM.

The Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

All Directors attended the EGM in person or by electronic means.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, December 30, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Ms. SI Wen as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.